Reliant Glycosciences, LLC

Reliant Glycosciences, LLC is a leading biotechnology company specializing in the development and commercialization of diagnostic and prognostic tools for IgA nephropathy (IgAN), a significant cause of chronic kidney disease. Based in Birmingham, Alabama, we are dedicated to improving patient outcomes through the GalD Assay, a standardized lectin-based ELISA that quantitatively measures galactose-deficient IgA1 (Gd-IgA1) in human serum. Our mission is to provide researchers and pharmaceutical companies with a critical biomarker to accelerate the development of effective therapies for this widespread condition. Founded in 2015 as a spin-out from the University of Alabama at Birmingham, Reliant Glycosciences leverages cutting-edge research to address an unmet need in IgAN management, aligning with the KDIGO guidelines and supporting the advancement of disease-specific treatments. We are committed to providing reliable and accessible tools to the IgAN research community and beyond.